I-Corps: Commercialization Evaluation of a Antibiotic Delivery System for Tb

I-Corps：结核病抗生素输送系统的商业化评估

• 批准号: 1535586
• 负责人: Thomas Manning
• 金额: $ 5万
• 依托单位: Valdosta State University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-05-15 至 2016-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1535586&HistoricalAwards=false
• 关键词: Corps; Commercialization; Evaluation; Antibiotic; Delivery

Tuberculosis is an infectious disease that has infected approximately one third of the planet's human population. The current pharmaceutical regiment used to treat the disease is a series of front line antibiotics. The microbe responsible for this malady, Mycobacterium tuberculosis, is building up a resistance to these drugs. These drug resistance strains of bacterium are emerging around the world. The pharmaceutical industry can produce the front line drugs economically on a large scale, so having to develop new drugs and new production methods would prove costly and likely result in an immunity situation again. Rather than attempting to discover new antibiotics, the proposed technology is focused on not only delivering known antibiotics to the bacterium more efficiently, but also hiding the drug from being recognized by the body's immune system.The proposed technology is focused on drug delivery associated with antibiotics for tuberculosis. Over the past forty years little work has been done in terms of developing new antibiotics. This team?s approach uses between one and three components that accelerates some biological action, such as the cells metabolism or a proteins task. As the activity of the cell increases, the team's theorem is that the antibiotic can go undetected by the body's immune system and have a more efficient uptake once its normal physiological processes are accelerated. Most drugs, such as antibiotics or cancer drugs have a mechanism of action that serve a singular mission, to stop some part of the cell from functioning. This research team has developed a delivery system for first and second line antibiotics used in the treatment of tuberculosis. It has been demonstrated to improve the efficacy of antibiotics such as capreomycin, amikacin, isoniazid and rifampici1-4.

结核病是一种传染病，感染了地球上大约三分之一的人口。目前用于治疗该病的药物主要是一系列一线抗生素。导致这种疾病的微生物，结核分枝杆菌，正在对这些药物产生抗药性。这些细菌的耐药性菌株正在世界各地出现。制药行业可以大规模经济地生产一线药物，因此必须开发新药和新的生产方法将证明成本高昂，并可能再次导致免疫状况。 这项技术并不是试图发现新的抗生素，而是不仅将已知的抗生素更有效地输送到细菌中，而且还将药物隐藏起来，使其不被人体免疫系统识别。这项技术的重点是与结核病抗生素相关的药物输送。在过去的40年里，在开发新抗生素方面几乎没有做什么工作。这个团队？这种方法使用一到三种成分来加速某些生物学行为，如细胞代谢或蛋白质任务。随着细胞活性的增加，该团队的理论是，抗生素可以不被人体的免疫系统检测到，并且一旦其正常的生理过程加速，就会有更有效的吸收。大多数药物，如抗生素或抗癌药物，都有一种作用机制，其作用是完成一个单一的使命，即阻止细胞的某些部分发挥功能。该研究小组开发了一种用于治疗结核病的一线和二线抗生素的输送系统。已证明其可提高卷曲霉素、阿米卡星、异烟肼和利福平等抗生素的疗效1 -4。